Astria Therapeutics, Inc. Common Stock
Symbol: ATXS (NASDAQ)
7.62
▲ (1.67%) 0.125
Company Description:
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.
Key Stats
- Today's Open: $7.47
- Today's High: $7.63
- Today's Low: $7.49
- Today's Volume: 21.31K
- Yesterday Close: $7.49
- Yesterday High: $7.9048
- Yesterday Low: $7.36
- Yesterday Volume: 460.23K
- Last Min Volume: 3.18K
- Last Min High: $7.615
- Last Min Low: $7.58
- Last Min VWAP: $7.60029
Company Profile
- Name: Astria Therapeutics, Inc. Common Stock
- Website: https://www.astriatx.com
- Listed Date: 2015-06-25
- Location: BOSTON, MA
- Market Status: Active
- CIK Number: 0001454789
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $422.70M
- Round Lot: 100
- Outstanding Shares: 56.43M
- Asset Type: CS
RECENT FILINGS FOR ATXS
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-12 | S-8 | View |
| 2025-08-12 | 10-Q | View |
| 2025-08-06 | 8-K | View |
| 2025-06-18 | SCHEDULE 13G | View |
| 2025-06-12 | 4 | View |
| 2025-06-12 | 4 | View |
| 2025-06-12 | 4 | View |
| 2025-06-12 | 4 | View |
| 2025-06-12 | 4 | View |
| 2025-06-12 | 4 | View |
| 2025-06-12 | 4 | View |
| 2025-06-12 | 4 | View |
| 2025-06-12 | 8-K | View |
| 2025-05-15 | SCHEDULE 13G/A | View |
| 2025-05-13 | 10-Q | View |
| 2025-05-12 | SCHEDULE 13G/A | View |
| 2025-04-28 | ARS | View |
| 2025-04-28 | DEFA14A | View |
| 2025-04-28 | DEF 14A | View |
Latest News on ATXS